OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
OmniScience and INmune Bio (
NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease (AD) clinical trial (the “AD02 trial”) using OmniScience’s flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents an innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management.
Omniscience Receives Patent for OCR Engine Using Major Advances in Applied Machine Learning
Omniscience today announced it has been granted a patent for technology that creates a breakthrough engine for Optical Character Recognition (OCR). Using innovative machine learning technology enables products based on this patent to handle a broader array of forms than more generic extraction tools such as those from Amazon, Google, or others.
